As life science research is becoming more complicated, requiring collaborative activity and significant resources, funding agencies, such as NIH and DOD, have shifted significant portions of their budgets towards supporting large scale, multi-project clinical activities of both academic institutions and companies. The funding agencies put forth great effort in creating and allocating budgets to programs […]
FreeMind sustains a growing network of leading companies and organizations, all with a strong and common interest in assisting the life science market and creating a common ground and collaborative framework for academia-industry collaborations. Our extensive and intimate understanding of the market, coupled with our designated knowledge of non dilutive funding sources and their promotion […]
Non dilutive funding is available for every conceivable kind of research or development effort, whether it is an academic or industry project. Government agencies, as well as state organizations and private foundations, release daily hundreds of different solicitations covering topics that are of interest to public health and medical and life science research. Although these […]
Industry-Academic partnerships drive life science discoveries to market, and the importance of sustaining and nurturing these relationships is high on the agenda of both industry and academic leaders. Over the past several years we are witnessing a changing direction at the NIH and other government granting agencies aimed at supporting these relationships. We will give […]
NIH alone awards roughly $5.5B annually to Cancer related R&D grants and contracts. The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation. In the upcoming webinar in the series of summer educational webinars, FreeMind’s VP, Ayal Ronen, will discuss key cancer […]
In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies. The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation. In this webinar […]
The Biomedical Advanced Research and Development Authority (BARDA) develops and purchases the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies. Interestingly, between 2010 and 2012, BARDA experienced a budget increase of some 60% from $337.5M to roughly $547M. For Life Science organizations, this translates into hundreds of millions of dollars in potential […]
FreeMind is proud to host the Michael J. Fox Foundation on the upcoming summer educational webinar focusing on Parkinson’s and other Neurological disorders. Parkinson’s is a complex disease that varies greatly among affected individuals. For The Michael J. Fox Foundation, there is one clear measure of success: delivering patients better treatments and, ultimately, a cure for Parkinson’s disease. Today, MJFF is […]